Lixisenatide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lixisenatide: From Type 2 Diabetes to Opsismodysplasia
One-Sentence Summary
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes mellitus, acting by stimulating insulin secretion in a glucose-dependent manner. The TxGNN model predicts it may be effective for Opsismodysplasia, a rare congenital skeletal dysplasia caused by INPPL1 gene loss-of-function mutations. Currently, no clinical trials and no publications support this specific repurposing direction — this prediction rests entirely on model inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 Diabetes Mellitus (GLP-1 receptor agonist class) |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 97.56% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on information embedded in the evidence pack, Lixisenatide is a GLP-1 receptor agonist that increases insulin secretion in a glucose-dependent manner, suppresses inappropriate glucagon secretion, and delays gastric emptying. Its efficacy in type 2 diabetes has been established in multiple large-scale clinical trials.
Opsismodysplasia is an ultra-rare autosomal recessive skeletal dysplasia caused by loss-of-function mutations in INPPL1, the gene encoding SHIP2 phosphatase. SHIP2 modulates PI3K/Akt signaling, a pathway involved in bone morphogenesis and chondrocyte differentiation. GLP-1 receptor agonists can indirectly influence PI3K/Akt via cAMP/PKA signaling, and modest evidence suggests GLP-1 may have a minor positive effect on bone mineral density in the context of metabolic disease.
However, the mechanistic link is considered extremely weak. Opsismodysplasia is a congenital structural disorder of skeletal morphogenesis arising from a permanent enzymatic deficiency — a fundamentally different problem from the metabolic dysregulation that GLP-1 receptor agonists address. The PI3K/Akt overlap is highly indirect, and no clinical or preclinical evidence links any GLP-1 receptor agonist to this condition. This prediction most likely reflects shared pathway nodes in the TxGNN knowledge graph rather than a therapeutically actionable relationship.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Lixisenatide is not currently registered or marketed in Singapore. No product authorization records exist in the Singapore Health Sciences Authority (HSA) database.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This is a model-only prediction (L5 evidence) with no supporting clinical trials or literature for opsismodysplasia. The mechanistic distance between GLP-1 receptor agonism and this congenital skeletal morphological disorder is too large to justify resource allocation at this stage.
To proceed, the following is needed:
- Preclinical mechanistic studies in INPPL1-deficient cell lines or animal models to determine whether GLP-1 receptor activation has any measurable effect on SHIP2-regulated bone morphogenesis
- Full retrieval of lixisenatide's detailed MOA from DrugBank API (currently a data gap)
- Safety data and package insert review from EMA or FDA product information (TFDA registration data unavailable)
- Review of GLP-1 receptor agonist class effects on bone and connective tissue in rare skeletal disease literature before assigning a research priority score
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.